top of page
For Investors
Kleis Therapeutics is developing a first‑in‑class TG2 inhibitor platform with the potential to transform treatment across multiple fibrotic diseases.
Our lead programme in fibrostenosing Crohn’s Disease addresses:
-
A large, underserved global market
-
A clear biological mechanism
-
A high‑value inflection point at IND
-
Strong interest from pharma in fibrosis‑modifying assets
We welcome discussions with investors interested in:
-
Pre‑Series A opportunities
-
Strategic partnerships
-
Co‑development or licensing pathways
-
SEIS and EIS Eligible
bottom of page